Secondary acute myeloid leukemia after etoposide therapy for retinoblastoma

Journal of Pediatric Hematology/Oncology

Volumn 29, Issue 9, 2007, Pages 646-648

  Weintraub, Michael ^a   Revel Vilk, Shoshana ^a   Charit, Mira ^a   Aker, Memet ^a   Pèer, Jacob ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Etoposide; Retinoblastoma; Secondary AML

Indexed keywords

CARBOPLATIN; EPIPODOPHYLLOTOXIN; ETOPOSIDE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER SUSCEPTIBILITY; CASE REPORT; FEMALE; GENETIC COUNSELING; HUMAN; MOSAICISM; MULTIPLE CYCLE TREATMENT; MYELOID LEUKEMIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RETINOBLASTOMA; RISK FACTOR;

ACUTE DISEASE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ETOPOSIDE; FEMALE; HUMANS; INFANT; LEUKEMIA, MYELOID; RETINAL NEOPLASMS; RETINOBLASTOMA; TREATMENT OUTCOME;

EID: 34548435581     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e318142b561     Document Type: Article

References (26)

1. Gurney JG, Bondy ML. Epidemiology of childhood cancer. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. Philadelphia: Lippincott Williams & Wilkins; 2006:1-13.
2. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355:1572-1582.
3. Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in five year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst. 2001;93:618-629.
4. Shields CL, Meadows A, Leahey AM, et al. Continuing challenges in the management of retinoblastoma with chemotherapy. Retina. 2004;24:849-862.
5. Friedman DL, Himelstein B, Shields CL, et al. Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol. 2000;18:12-17.
6. Abramson DH, Frank CM. Second non-ocular tumors in survivors of bilateral retinoblastoma: a possible age effect on radiation-related risk. Ophthalmology. 1998;105:573-580.
7. Roarty JD, McLean IW, Zimmerman LE. Incidence of second neoplasms in patients with bilateral retinoblastoma. Ophthalmology. 1998;95:1583-1587.
8. Kleinerman RA, Tucker MA, Tarone RE, et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol. 2005;23:2272-2279.
9. Kleinerman RA, Tucker MA, Abramson DH, et al. Risk of soft tissue sarcomas by individual subtypes in survivors of hereditary retinoblastoma. J Natl Cancer Inst. 2007;99:24-31.
10. Smith MA, Rubinstein L, Ungerleider RS. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks. Medical Pediatr Oncol. 1994;23:86-98.
11. Pui CH, Ribeiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med. 1991;325:1682-1687.
12. Whitlock JA, Greer JP, Lukens JN. Epipodophyllotoxin-related leukemia: identification of a new subset of secondary leukemia. Cancer. 1991;68:600-604.
13. Metzler M, Strissel PL, Strick R, et al. Emergence of translocation t(9;11)-positive leukemia during treatment of childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2004;41:291-296.
14. Loning L, Zimmermann M, Reiter A, et al. Secondary neoplasms subsequent to Berlin-Frankfurt-Munster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. Blood. 2000;95:2770-2775.
15. Leung W, Sandlund JT, Hudson MM, et al. Second malignancy after treatment of childhood non-Hodgkin lymphoma. Cancer. 2001;92:1959-1966.
16. Schneider DT, Hilgenfeld E, Schwabe D. Acute myelogenous leukemia following treatment for germ cell tumors in children. J Clin Oncol. 1999;17:3226-3233.
17. Shearer P, Kapoor G, Beckwith JB, et al. Secondary acute myelogenous leukemia in patients previously treated for childhood renal tumors: a report from the National Wilms Tumor Study Group. J Pediatr Hematol Oncol. 2001;23:109-111.
18. Haupt R, Fears TR, Rosso P, et al. Increased risk of secondary leukemia after single agent treatment with etoposide for Langerhans cell histiocytosis. Pediatr Hematol Oncol. 1994;11:499-507.
19. Le Deley M-C, Leblanc T, Shamsaldin A, et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case control study by the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol. 2003;21:1074-1081.
20. Smith MA, Rubinstein L, Anderson JR, et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol. 1999;17:569-577.
21. Stine KC, Saylors RI, Sawyer JR, et al. Secondary acute myeloid leukemia following safe exposure to etoposide. J Clin Oncol. 1997;15:1583-1586.
22. Dunkel IJ, Chantada GL, Fandino AC, et al. Lack of activity of oral etoposide for relapsed intraocular retinoblastoma. Ophthalmic Genet. 2004;25:25-29.
23. Felice MS, Zubizarreta PA, Chantada GL, et al. Acute myeloid leukemia as a secondary malignancy: report of 9 pediatric patients in a single institution in Argentina. Med Pediatr Oncol. 1998;30:160-164.
24. Abramson DH, Frank CM. Second non-ocular tumors in survivors of bilateral retinoblastoma: a possible age effect on radiation-related risk. Ophthalmology. 1998;105:573-580.
25. Fletcher O, Easton D, Anderson K, et al. Lifetime risks of common cancers among retinoblastoma survivors. J Natl Cancer Inst. 2004;96:357-363.
26. Sandler ES, Friedman JF, Mustafa MM, et al. Treatment of children with epipodophyllotoxin-induced secondary acute myleoid leukemia. Cancer. 1997;79:1049-1054.